{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"It will be determined if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes.","groups":[{"description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","id":"OG000","title":"Cohort I (Initial IHC Within 42 Days)"},{"description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","id":"OG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)"}],"populationDescription":"no data was collected","reportingStatus":"POSTED","timeFrame":"Up to 8 weeks after last protocol treatment","title":"Induction of Host T Cells Reactive With Tumor Associated Epitopes","type":"SECONDARY"}